Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission

[1]  C. Bloomfield,et al.  Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia. , 2019, Blood.

[2]  S. Asthana,et al.  Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. , 2019, Cancer discovery.

[3]  M. Konopleva,et al.  Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3‐internal tandem duplication genotypes , 2018, Cancer.

[4]  J. Kanda,et al.  Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia. , 2018, Blood advances.

[5]  Hong-jie Shen,et al.  Impact of FLT3-ITD length on prognosis of acute myeloid leukemia , 2018, Haematologica.

[6]  B. Ko,et al.  Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor‐risk factor in de novo acute myeloid leukemia patients , 2018, European journal of haematology.

[7]  B. Ko,et al.  Concomitant WT1 mutations predict poor prognosis in acute myeloid leukemia patients with double mutant CEBPA , 2018, Haematologica.

[8]  Chieh-Yu Liu,et al.  Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome , 2018, Blood Cancer Journal.

[9]  M. Levis,et al.  How I treat FLT3-mutated AML. , 2017, Blood.

[10]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[11]  Claude Preudhomme,et al.  A 17-gene stemness score for rapid determination of risk in acute leukaemia , 2016, Nature.

[12]  B. Ko,et al.  Genetic alterations and their clinical implications in older patients with acute myeloid leukemia , 2016, Leukemia.

[13]  N. Schmitz,et al.  Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  Chieh-Yu Liu,et al.  Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia , 2016, Oncotarget.

[15]  L. Bullinger,et al.  Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. , 2014, Blood.

[16]  Bor-Sheng Ko,et al.  Prognostic implication of gene mutations on overall survival in the adult acute myeloid leukemia patients receiving or not receiving allogeneic hematopoietic stem cell transplantations. , 2014, Leukemia research.

[17]  R. Hills,et al.  Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. , 2014, Blood.

[18]  Chieh-Yu Liu,et al.  IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution , 2014, American journal of hematology.

[19]  B. Ko,et al.  Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome , 2014, Blood Cancer Journal.

[20]  J. Esteve,et al.  Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. , 2013, Blood.

[21]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[22]  M. Caligiuri,et al.  Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias. , 2012, Blood.

[23]  J. Esteve,et al.  Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Angelo J. Canty,et al.  Stem cell gene expression programs influence clinical outcome in human leukemia , 2011, Nature Medicine.

[25]  T. Haferlach,et al.  Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia , 2011, Leukemia.

[26]  Y. Chao,et al.  Sensitive measurement of quantity dynamics of FLT3 internal tandem duplication at early time points provides prognostic information. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  Torsten Haferlach,et al.  Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Chieh-Yu Liu,et al.  AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. , 2009, Blood.

[29]  Svetlana K. Eden,et al.  Immortal time bias in critical care research: Application of time-varying Cox regression for observational cohort studies* , 2009, Critical care medicine.

[30]  Axel Benner,et al.  Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.

[31]  H. Tien,et al.  Characterization of acute myeloid leukemia with PTPN11 mutation: the mutation is closely associated with NPM1 mutation but inversely related to FLT3/ITD , 2008, Leukemia.

[32]  Adam J Mead,et al.  The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. , 2008, Blood.

[33]  O. Yli-Harja,et al.  Global Gene Expression Profile of Human Cord Blood–Derived CD133+ Cells , 2006, Stem cells.

[34]  Chunaram Choudhary,et al.  Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. , 2005, Cancer research.

[35]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[36]  G. Ehninger,et al.  Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia , 2003, Genes, chromosomes & cancer.

[37]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[38]  E. Estey,et al.  CME Information: Acute myeloid leukemia: 2016 Update on risk-stratification and management , 2016 .

[39]  S-J Wu,et al.  Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia , 2014, Leukemia.

[40]  Chieh-Yu Liu,et al.  DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. , 2012, Blood.

[41]  Chieh-Yu Liu,et al.  Clinical Trials and Observations , 2022 .

[42]  H. Kantarjian,et al.  Acute myeloid leukemia , 2018, Methods in Molecular Biology.

[43]  R Simon,et al.  A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. , 1984, Statistics in medicine.